Clinical Trials Logo

Mantle Cell Lymphoma (MCL) clinical trials

View clinical trials related to Mantle Cell Lymphoma (MCL).

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05144347 Terminated - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

Start date: April 12, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1, non-randomized, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical antitumor activity of XL114 administered alone orally to subjects with Non-Hodgkin's Lymphoma (NHL). The objectives of the study also include determining the recommended dose (RD) and/or maximum tolerated dose (MTD) of XL114.

NCT ID: NCT03571828 Terminated - Clinical trials for Follicular Lymphoma (FL)

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

Start date: October 29, 2018
Phase: Phase 1
Study type: Interventional

Evaluate the safety and tolerability of AMG 562 in adult subjects with DLBCL, MCL, or FL. Estimate the maximum tolerated dose (MTD) and/or a biologically active dose (e.g., recommended phase 2 dose [RP2D])

NCT ID: NCT02914938 Terminated - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

Start date: October 2016
Phase: Phase 1
Study type: Interventional

A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL